Health Economics›Non-small cell lung cancer›Consolidation after definitive therapy for inoperable disease

Consolidation after definitive therapy for inoperable disease

Non-small cell lung cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	~5.4 mo	~10.4 mo	~8	~R 40 246 PFS proxy · indirect	36
Observation Partial	—	—	—	5.5 mo	23.2 mo	—	—	2

2 of 2 regimens shown